#152708

A2780cis Cell Line

Please Enter Your Email ID
Email ID

Cat. #152708

A2780cis Cell Line

Cat. #: 152708

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Ovary

Disease: Cancer

Model: Tumour line

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Timothy Ward

Institute: National Cancer Institute

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: A2780cis Cell Line
  • Alternate name: A2780 cis; A2780/cis; A2780-cis; A2780CIS; A2780cis Cells; cisplatin-resistant cell line
  • Cancer: Gynaecologic cancer
  • Cancers detailed: Human ovarian carcinoma
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: A2780
  • Organism: Human
  • Tissue: Ovary
  • Disease: Cancer
  • Growth properties: Adherant
  • Model: Tumour line
  • Conditional: Yes
  • Description: A2780 cell line resistant to cisplatin. Background and Research Application The cisplatin-resistant A2780cis cell line has been developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line (catalogue no. 152706) to increasing concentrations of cisplatin. This cell line was derived from a patient with ovarian endometroid adenocarcinoma. A2780cis is cross-resistant to melphalan, adriamycin and irradiation. An increased ability to repair DNA damage as well as cytogenetic abnormalities has been observed. In order to retain resistance cisplatin has to be added to the media for every passage. In addition to this matched pair of drug-sensitive/resistant cell lines an adriamycin-resistant cell line, A2780adr (catalogue no. 152707), has been isolated from the same parental line. A2780cis has been used in a variety of experiments, including studying the cytotoxic effects of platinum (II) complexes and gold (I)-triphenylphosphine complexes with hypoxanthine-derived ligands. It has also been used to study the effects of cancer-cell specific oligopeptides.
  • Application: Toxicity testing, drug resistance studies
  • Production details: Split sub-confluent cultures (70-80%) 1:5 to 1:20 i.e. seeding at 1x1,000 to 1x10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Cells will attach slowly after resuscitation and take up to 7 days to reach confluency. Recommendation: resuscitate cells in media without cisplatin. Add after subculture of attached cells.
  • Additional notes: Points of Interest This cell line has also been used in toxicity testing and drug resistance studies. Karyotype: Modal no. 46 STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 13 D16S539: 11,13 D5S818: 11 D7S820: 10 THO1: 6 TPOX: 8,10 vWA: 15,16 Concentration Vial has between 1-5 million cells as standard, however this may vary.
  • Cellosaurus id: CVCL_1942

Target Details

  • Target: Cisplatin resistance

Applications

  • Application: Toxicity testing, drug resistance studies
  • Application notes: Points of Interest Karyotype: Modal no. 46 STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 13 D16S539: 11,13 D5S818: 11 D7S820: 10 THO1: 6 TPOX: 8,10 vWA: 15,16 Concentration Vial has between 1-5 million cells as standard, however this may vary.

Handling

  • Format: Frozen
  • Growth medium: RPMI 1640 + 2mM Glutamine + 1muM cisplatinum + 10% Foetal Bovine Serum (FBS). To retain resistance cisplatin must be added to the media every 2-3 passages.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: A2780 Cell Line ; A2780ADR Cell Line

References

  • Wang et al. 2015. Theranostics. 5(4): 431-442. PMID: 25699101.
  • Starha et al. 2014. PLoS One. 9(3):e90341. PMID: 24603594
  • Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
  • Marcotte et al. 2012. Cancer Discov. 2(2):172-189. PMID: 22585861.
  • Rothenberg et al. 2010. Cancer Res. 70(6):2158-2164. PMID: 20215515.
  • Masuda et al. 1988. Cancer Res. 48(20):5713-5716. PMID: 3139281.
  • Behrens et al. 1987. Cancer Res. 47(2):414-418. PMID: 3539322.